Inhibition of Aβ 42 Tripeptide compounds that aggregate and reduce their cytotoxic effects

Through tripeptide compounds such as ERW and WRR, using Python database and molecular dynamic analysis, the problem of encephalitis caused by existing Alzheimer's disease treatment drugs is solved, and effective inhibition of Aβ42 aggregation and reduction of cytotoxicity are achieved. New treatments for Alzheimer's disease.

CN118126120BActive Publication Date: 2024-12-06HAINAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410276051.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-14
Publication Date
2024-12-06
Estimated Expiration
2043-09-14

AI Technical Summary

Technical Problem

Existing Alzheimer's disease treatment drugs, such as Aβ42 monoclonal antibodies, may cause encephalitis, and the pathological complexity of Alzheimer's disease makes the development of therapeutic drugs face great challenges, making it difficult to effectively inhibit Aβ42 aggregation and reduce its cellular toxicity. effect.

Method used

Using tripeptide compounds, including glutamate-arginine-tryptophan (ERW) and tryptophan-arginine-arginine (WRR), a tripeptide database is constructed through Python language, using molecular docking and molecular dynamics. The software screened out tripeptides that could bind to Aβ42 and conducted pharmacological experiments to verify its effect on inhibiting Aβ42 aggregation and cytotoxic effects.

Benefits of technology

It is verified that WRR and ERW and their compound mixtures have a significant inhibitory effect on Aβ42 aggregation, which reduces its cytotoxicity on SH-SY5Y nerve cells, provides potential drug or food applications for the treatment of Alzheimer's disease, and slows down Aβ42 aggregation and Its cytotoxic effect is caused.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118126120B_ABST
    Figure CN118126120B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for inhibiting Aβ 42 The present invention uses Python language to construct a tripeptide database, and screens out the tripeptide compounds that bind to Aβ through molecular docking. 42 The molecular dynamics method was used to analyze the binding of the five tripeptides (ERW, QRW, RRR, RRW and WRR) to Aβ 42 Protein interactions, complex Aβ revealed by Pull-out plot structural plausibility analysis and umbrella sampling binding energy analysis 42 ‑WRR and Aβ 42 The ERW docking conformation is effective, and WRR and ERW are active against Aβ 42 We designed and implemented pharmacological experiments to verify the effects of WRR, ERW and their compound mixture on Aβ 42 Aggregation is well inhibited, reducing the secretion and expression of Aβ 42 Cytotoxic effect on SH‑SY5Y neural cell line.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, in particular to inhibiting Aβ 42 Aggregation and reduced cytotoxicity of tripeptide compounds. Background Art

[0002] Alzheimer's disease is a neurodegenerative disease with the main pathological characteristics of amyloid-β (Aβ) aggregation into amyloid plaques and Tau protein hyperphosphorylation. After Aβ aggregation, excessive activation of immune cells causes brain inflammation; destroys synapses and neurons; causes neuronal necrosis, and spreads chromatin and other cell contents to the surrounding brain tissue (unpublished data). Aβ (Aβ) contains 42 amino acids. 42 ) is the main species that forms amyloid plaques, not Aβ 40 . Alzheimer's disease is one of the top ten causes of death in developed countries. It is not only an intellectually disabling disease, but also a cruel process of death. The total number of Alzheimer's patients worldwide has exceeded 50 million. Currently, the only clinical drug targeting the pathological marker of Alzheimer's disease, Aβ protein, is the anti-amyloid protein Aβ approved for marketing by the US FDA in 2021 through an expedited review pathway. 42 Monoclonal antibodies, however, several clinical trials in the past have shown that Aβ 42 Monoclonal antibodies can cause encephalitis, and the research and development of new antibody drugs by many pharmaceutical companies has ended in the clinical stage. The pathological complexity of Alzheimer's disease poses a great challenge to the task of developing specific drugs for the treatment of Alzheimer's disease. Our previous basic research shows that Aβ 42 The monomer is a globular protein. As the degree of polymerization increases, an S-shaped tubular structure is formed, which has the lowest system free energy. In this patent, we propose to inhibit Aβ 42 A tripeptide compound and a compound thereof that aggregates and reduces its cytotoxic effect. Summary of the invention

[0003] The present invention aims to provide a method for inhibiting Aβ 42 A tripeptide compound with aggregation and reduced cytotoxicity and a compound thereof are provided to solve the problems raised in the above background technology.

[0004] To achieve the above object, the present invention provides the following technical solution: a tripeptide compound, wherein the tripeptide compound comprises ERW or WRR.

[0005] Preferably, the ERW is glutamate-arginine-tryptophan, and the WRR is tryptophan-arginine-arginine.

[0006] Preferably, the tripeptide compound is used to inhibit Aβ 42 Gather.

[0007] Preferably, the tripeptide compound is used to reduce Aβ 42 Cytotoxic effect.

[0008] Preferably, the method for preparing the tripeptide compound is characterized by comprising the following steps:

[0009] Step 1: Use Python to write ChemScript scripts to create a structure database of all tripeptides composed of 20 L-α amino acids;

[0010] Step 2: Screening of pentameric oligomers of Aβ from the protein database 42 The protein molecular structure is the target protein conformation;

[0011] Step 3: Five-membered oligomer Aβ 42 For the target protein, molecular docking software and the constructed tripeptide structure database were used for molecular docking to screen out the tripeptide with the best docking state;

[0012] Step 4: Use GROMACS molecular dynamics software to analyze the docking of the five tripeptides screened and the five-membered polymer Aβ 42 The binding free energy of

[0013] Step 5: Pharmacological experiments to analyze the inhibition of Aβ by a mixture of five tripeptides 42 Aggregation and reduction of Aβ 42 Caused cytotoxic effects.

[0014] Preferably, the tripeptide compound is used in medicines and foods for preventing and treating Alzheimer's disease.

[0015] Preferably, the tripeptide compound is used in medicine and food.

[0016] Technical effects and advantages of the present invention:

[0017] The present invention uses Python language to construct a tripeptide database, and screens out peptides that can bind to Aβ through molecular docking. 42 The molecular dynamics method was used to analyze the binding of the five tripeptides (ERW, QRW, RRR, RRW and WRR) to Aβ 42 Protein interactions, complex Aβ revealed by Pull-out plot structural plausibility analysis and umbrella sampling binding energy analysis 42 -WRR and Aβ 42 The docking conformation of WRR and ERW is effective. On this basis, pharmacological experiments are designed and implemented to verify the effects of WRR, ERW and their complex mixture on Aβ 42 Aggregation is well inhibited, reducing the secretion and expression of Aβ 42Cytotoxicity to SH-SY5Y neural cell line. The main pathological feature of Alzheimer's disease is Aβ in the patient's brain 42 Aggregation forms plaques. Based on this pathogenesis, a compound mixture composed of WRR and ERW can be used in drugs or foods to slow down the progression of Aβ. 42 Pathological processes such as aggregation and the cytotoxic effects it causes. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The tripeptide obtained by molecular docking of the present invention and Aβ 42 Schematic diagram of the five-membered polymer core binding.

[0019] Figure 2 The tripeptide ligand of the present invention and Aβ 42 Pull-out diagram of the dimer complex.

[0020] Figure 3 The tripeptide ligand of the present invention and Aβ 42 Structural plausibility analysis of the dimer complex.

[0021] Figure 4 Molecular dynamics analysis of the five tripeptide compounds and Aβ 42 Schematic diagram of the binding free energy of the five-membered aggregation core.

[0022] Figure 5 ThT method was used to detect the inhibitory effects of two tripeptides and their compound on Aβ 42 Schematic diagram of the effect of aggregation.

[0023] Figure 6 Electron microscopy observation of the effects of the two tripeptides of the present invention on Aβ 42 Schematic diagram of the influence of aggregation morphology.

[0024] Figure 7 ELISA assay to detect the effects of two tripeptides on secreted Aβ 42 Schematic diagram of the effects of SH-SY5Y cell expression.

[0025] Figure 8 Microscopic observation of the effects of WRR and ERW on secreted Aβ 42 Schematic representation of the effects on SH-SY5Y cell survival.

[0026] Fig. 9 Flow cytometry was used to detect the effects of two tripeptides on secreted Aβ 42 Schematic diagram of the effects of reactive oxygen species (ROS) production in SH-SY5Y cells. DETAILED DESCRIPTION

[0027] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0028] The present invention provides Figure 1-9 The tripeptide compound shown, the tripeptide compound comprising glutamic acid-arginine-tryptophan (ERW) or tryptophan-arginine-arginine (WRR), is used to inhibit Aβ 42 Aggregation and reduction of Aβ 42 A compound mixture of tripeptide compounds with cytotoxic effects, a tripeptide compound or a compound mixture thereof for preventing and treating Aβ 42 Diseases related to aggregation and its cytotoxicity, or for the treatment of diseases affecting Aβ 42 Disease pathologies associated with aggregation and cytotoxicity contain glutamate-arginine-tryptophan (ERW) or tryptophan-arginine-arginine (WRR).

[0029] Preferably, the research method of the tripeptide compound or its compound mixture comprises the following steps:

[0030] Step 1: Use Python to write ChemScript scripts to create a structure database of all tripeptides composed of 20 L-α amino acids;

[0031] Step 2: Screening the pentameric oligomer Aβ from the protein database (PDB) 42 The protein molecular structure of (No. 5oqv) is the target protein conformation;

[0032] Step 3: Five-membered oligomer Aβ 42 For the target protein, molecular docking software and the tripeptide structure database we built were used for molecular docking to screen out the tripeptide with the best docking state;

[0033] Step 4: Use GROMACS molecular dynamics software to analyze the docking of the five tripeptides screened and the five-membered polymer Aβ 42 (5oqv) binding free energy;

[0034] Step 5: Pharmacological experiments to analyze the inhibitory effects of two tripeptides (WRR and EWR) on Aβ 42 Aggregation and reduction of Aβ 42 Caused cytotoxic effects.

[0035] Among them, the five tripeptides screened in step 3 include ERW, QRW, RRR, RRW and WRR. These five tripeptides are related to Aβ42 Combines the best tripeptides.

[0036] Furthermore, the analysis results obtained in steps 4 and 5 showed that the complex Aβ 42 -WRR and Aβ 42 -ERW docking conformation is effective, and WRR and ERW are active against Aβ 42 Aggregation plays an effective inhibitory role, which is analyzed by Pull-type diagram structure rationality analysis and umbrella sampling binding energy analysis. The principle of Pull-type diagram structure rationality analysis is to evaluate the rationality of the backbone conformation of two adjacent peptide units through the minimum contact distance between non-bonded atoms in the protein, and to represent the allowed and unallowed conformations in the protein. The number of amino acids in the unallowed area should be less than 5% of the total number of amino acids. Tripeptide and Aβ 42 The binding free energy of the tripeptide was obtained by analyzing the change in the system free energy during the process of pulling the tripeptide away from the binding complex; the greater the change in the system free energy, the closer the tripeptide is to Aβ 42 The higher the binding free energy.

[0037] Furthermore, the analysis results obtained from the pharmacological experiment in step 5 confirmed the effects of WRR and ERW and their compound mixture on Aβ 42 Aggregation is inhibited and can be used to reduce secreted Aβ expression 42 Cytotoxic effect on SH-SY5Y neural cell line, pharmacological experiments include ELISA experiment, cell apoptosis experiment and cell ROS detection.

[0038] Furthermore, the tripeptide compound and its compound mixture are used in medicine and food, and the medicine and food can be used to slow down Aβ 42 Aggregation and its cytotoxic pathological process, where the compound mixture refers to the compound composed of WRR and ERW. 42 The main driving force of aggregation is the free energy reduced by hydrophobic interaction (a comprehensive manifestation of three interactions). The tripeptide and its compound of the present invention have a strong affinity with Aβ 42 Binding, inhibiting its excessive aggregation and its cytotoxic effects.

[0039] The present invention uses Python language to construct a tripeptide database, and screens out peptides that can bind to Aβ through molecular docking. 42 The molecular dynamics method was used to analyze the binding of the five tripeptides (ERW, QRW, RRR, RRW and WRR) to Aβ 42 Protein interactions, complex Aβ revealed by Pull-out plot structural plausibility analysis and umbrella sampling binding energy analysis 42 -WRR and Aβ 42 -ERW docking conformation is effective and WRR and ERW are active against Aβ 42On this basis, pharmacological experiments were designed and implemented to verify the effects of WRR, ERW and their compound mixture on Aβ 42 Aggregation is well inhibited, reducing the secretion and expression of Aβ 42 Cytotoxicity to SH-SY5Y neural cell line. The main pathological feature of Alzheimer's disease is Aβ in the patient's brain 42 Aggregation forms plaques. Based on this pathogenesis, a compound mixture composed of WRR and ERW can be used in drugs or foods to slow down the progression of Aβ. 42 Pathological processes such as aggregation and the cytotoxic effects it causes.

[0040] Specific implementation method 1: Using information science technology to analyze tripeptide compounds and five-membered polymer Aβ 42 methods of interaction;

[0041] (1) Construction of a tripeptide compound structure database: ChemScript script was written in Python to establish a structural database in the sdf (Structure Data File) format of all tripeptide compound molecular structures composed of 20 random combinations of L-α-amino acids;

[0042] (2) Search the protein structure database (PDB) of the Research Collaborative on Structural Bioinformatics (RCSB) in the United States and download Aβ 42 The three-dimensional structure data of the aggregation core (number 5oqv). The downloaded structure file was renamed 5oqvPentamer.pdb and saved as the target protein structure file for molecular docking;

[0043] (3) Molecular docking was performed using molecular docking software, 5oqvPentamer was used as the docking receptor, and the tripeptide compound structure database constructed above was used for molecular docking. The docking results were ranked according to the optimized binding energy, and the five tripeptide compounds with the best docking status were selected for subsequent molecular dynamics and pharmacological analysis. The five tripeptide compounds screened by molecular docking were ERW, QRW, RRR, RRW and WRR;

[0044] (4) Molecular dynamics analysis of the interaction between five tripeptides and Aβ 42The GROMACS molecular dynamics analysis software (version 2020.03) was installed on the Ubuntu (version 18.04) Linux operating system, using the GPU hybrid parallel computing mode supported by CUDA (Compute Unified Device Architecture), and the AMBER99SB force field optimized for ab initio calculations of protein structures and TIP3P to clarify the water molecule model, to analyze the binding stability and interaction energy of 5 tripeptide compounds and Aβ 42 Binding stability and binding free energy. The change in free energy is a very important physical quantity that determines the direction of the reaction. Free energy is the basis for judging whether a process can proceed spontaneously in the second law of thermodynamics. Gibbs free energy (ΔG) reflects the level of binding energy. This study used GROMACS (2020.03) software to calculate the change in Gibbs free energy (ΔG) when the ligand is pulled away from the target protein along the reaction axis (ξ) using umbrella sampling and weighted histogram method (WHAM) to explore the interaction between tripeptide and pentapeptide compound substrates and Aβ. 42 The stability of monomer binding. First, the ligand of the protein-ligand complex structure screened by molecular docking was minimized and the complex structure was corrected, and then the GROMACS topology file was generated by the pdb2gmx command. The GROMOS96 53a6 force field and SPC216 water molecule model solvent were selected. The content of the topol_Protein_chain_H.itp file was corrected. The system analysis unit box size was defined as a rectangular box of 6.0x 7.0x15.0nm, and the Aβ bound to the tripeptide and pentapeptide 42 The center position of the protein complex is 3.0, 3.5, 12.5 (x, y, z). The protein-ligand complex structure is placed on one side of the rectangular unit box. The unit box is filled with water molecules, and 0.1M sodium chloride is added to the system to balance the system charge. The reference atom is set to Aβ 42 The carbonyl carbon atom of glycine at position 29 and the Cα of the second amino acid of the tripeptide or the Cα of the third amino acid of the pentapeptide. Before the pulling and umbrella sampling stages, the pressure balance shown above was used. After system energy minimization and pressure balance, the ligand substrate was pulled away from the protein complex along the reaction axis (ξ) by applying a resonant force at a constant speed of 0.01nm / ps during 250,000 time steps and generating a series of configuration data. System configurations with a center distance of no more than 0.2nm were selected as analysis windows for umbrella sampling analysis, each with 5,000,000 time steps, and then the weighted histogram analysis method was used to obtain the Gibbs free energy change curve in the protein-ligand complex system.

[0045] Specific embodiment 2: Using ThT to detect the inhibition of Aβ by tripeptide compounds and their compound mixtures 42 Aggregation of Aβ 42 They aggregate with each other in a β-sheet conformation, generating three hydrophobic regions and burying the hydrophobic amino acids inside the protein complex, thereby reducing the free energy of the system. ThT is a commonly used 42 benzothiazole fluorescent dye, which can specifically bind to Aβ 42 The β-sheet structure of ThT enhances the fluorescence after binding. 42 The more polymerized β-sheet structures there are, the stronger the fluorescence intensity of the system is. 42 Outside the polymerized fiber, does not interfere with Aβ 42 Aggregation, therefore, ThT is often used to analyze and determine Aβ 42 Formation of polymeric fibers;

[0046] (1) Aβ 42 and tripeptide sample treatment, Aβ 42 The powder was dissolved in 1.0% NH4OH to form a 1 mM stock solution, and the solid powder of the dipeptide compound was dissolved in 10 mM phosphate buffer (pH 7.4) (PBS) to form a 1 mM stock solution. In subsequent experiments, all stock solutions were diluted with 10 mM PBS to form working solutions of different concentrations before use;

[0047] (2) Using Thioflavin T (ThT) to detect the fluorescence of tripeptide compounds and their compound mixtures on Aβ 42 To inhibit the aggregation, 0.0128 mg of ThT powder was dissolved in PBS, stirred thoroughly to dissolve, and the volume was adjusted to 10 mL to prepare a 4 mM ThT stock solution. In a 96-well plate with a black wall and a transparent bottom, Aβ was added in sequence to a final concentration of 10 μM. 42 , 10 μM of a tripeptide compound or a tripeptide compound mixture (5 μM of each of the two tripeptides) and 16 μM of ThT, the total reaction volume was 125 μL, 5 replicates were set for each group, the samples were mixed evenly, incubated at 37°C for 24 hours, and after the incubation, placed in a Synergy H1 microplate reader, set the excitation wavelength to 450 nm, and detect the fluorescence intensity at a wavelength of 485 nm.

[0048] Specific implementation method 3: Observation of Aβ using transmission electron microscopy (TEM) 42 Aggregation morphology of Aβ in the experimental group 42 Four times the amount of Aβ 42 The tripeptide WRR and ERW were co-incubated with the control group containing only Aβ 42 ;

[0049] (1) 10 μl of the sample incubated in a constant temperature shaker at 37°C for 48 h was taken out and dropped onto a carbon-supported deionized copper mesh. Then, 10 μl of a 2% phosphotungstic acid solution was dropped for negative staining. After drying, the sample was observed using a transmission electron microscope system with an accelerating voltage of 200 kV and a scale of 200 nm. Aβ 42 The final concentration was 10 μM, and the final concentration of the tripeptides WRR and ERW was 40 μM.

[0050] (2) Aβ alone 42 After 48 hours of incubation, the fibrils were tightly packed into plaques and crossed each other. After adding the tripeptide WRR and ERW, Aβ was incubated for 48 hours. 42 The amorphous aggregates were small in size. Transmission electron microscopy results showed that the addition of the tripeptide compound prevented Aβ from forming to some extent. 42 The formation of fibril aggregates produces only a small amount of oligomers.

[0051] Specific implementation method 4: ethidium bromide method (EB) to explore the effect of tripeptide on Aβ42 cytotoxicity;

[0052] (1) After SH-SY5Y cells were revived, cells in the logarithmic growth phase and in good condition were inoculated into a 12-well cell culture plate for overnight culture. When the growth abundance reached 75-80%, the pcDNA3.1-Aβ42 plasmid was transfected into the cells, allowing the SH-SY5Y cells to secrete and express Aβ42 extracellularly.

[0053] (2) After transfection, three replicates were set for each treatment group, and two short peptides ERW and WRR were added at final concentrations of 10 μM and 50 μM for 24 hours. Ethidium bromide was added to each group of cells at a final concentration of 1 mg / ml and the cells were moved to a carbon dioxide incubator and incubated for 10 minutes.

[0054] (3) Using an automatic inverted fluorescence microscope (Axio Observer 7), set the excitation wavelength to 545 nm and measure the emission wavelength at 590 nm to observe the cells. Dead cells show red fluorescence. Image J was used to count dead cells. The results showed that the number of dead cells in SH-SY5Y cells transfected with pcDNA3.1-Aβ42 plasmid was significantly reduced in the case of tripeptide pretreatment compared with the group without oligopeptide treatment, and it was dose-dependent.

[0055] Specific implementation method 5: Flow cytometry detection of tripeptide to Aβ 42 Induced apoptosis

[0056] SH-SY5Y cells in the logarithmic growth phase were selected and digested with trypsin and seeded in 12-well cell plates for 24 hours. The cells were then transfected with pcDNA3.1-Aβ using Lipofectamine 2000 reagent. 42 Plasmid was introduced into SH-SY5Y cells to enable the cells to secrete Aβ 42 After transfection, three replicates were set for each dosing group, and two short peptides ERW and WRR were added with final concentrations of 10μM and 50μM for treatment for 24 hours. The apoptotic cells and necrotic cells were marked with the apoptosis kit of Shanghai Biosai Biotechnology, and the apoptosis level of SH-SY5Y cells was detected by flow cytometry.

[0057] Specific implementation method 6: Flow cytometry detection to explore the effect of tripeptide on Aβ 42 Stimulates the production of reactive oxygen species in cells;

[0058] (1) Trypsin-digested SH-SY5Y cells were inoculated into 24-well cell plates, with approximately 10 cells in each well. 6 The cells were transferred to a carbon dioxide incubator and cultured for 24 hours, and then transfected with pcDNA3.1-Aβ using a PEI 40K transfection kit 42 Plasmid was introduced into SH-SY5Y cells, so that SH-SY5Y cells could secrete Aβ 42 , the experimental groups were treated with WRR and ERW at final concentrations of 10 μM and 50 μM at 37°C for 24 h, and three replicates were set for each tripeptide treatment group;

[0059] (2) Observe the cell status and take photos under an inverted microscope;

[0060] (3) Treat cells with reactive oxygen species detection reagent, select the FL1 channel of the flow cytometer, set the excitation wavelength to 488 nm, and measure the emission wavelength at 530 nm. Microscopic observation showed that the tripeptide itself had no neurotoxic effect on SH-SY5Y cells, and WRR and ERW could effectively inhibit the secretion of Aβ by SH-SY5Y cells. 42 aggregation and eliminate Aβ 42 The toxic effect of aggregation on cells, flow cytometry results show: transfection with pcDNA3.1-Aβ 42 The level of induced ROS in SH-SY5Y cells pretreated with the tripeptide plasmid was significantly reduced compared with the untreated group, and the Aβ 42 induced ROS formation in SH-SY5Y cells.

[0061] Specific implementation method 7: MTT (thiazolyl blue) method to detect the effects of tripeptide and its compound on Aβ 42 Effects of cytotoxicity;

[0062] When SH-SY5Y cells were in the logarithmic growth phase, they were trypsinized, the cells were counted, and the cells were evenly seeded into a 96-well plate, with the number of cells per well being 5 x 10 3 After 24 hours of culture, transfection was performed to secrete Aβ 42 Different concentrations of WRR (10 μM), EWR (10 μM) or WRR / EWR (5 μM each) mixed solution were added to SH-SY5Y cells containing protein, blank wells were set as cell culture medium, control wells were normal untransfected cells, zero wells were transfected cells with phosphate buffer, 4 replicates were set, DPBS buffer was added to the edge wells to prevent the solution in the sample wells of the experimental group from evaporating, and the cells were cultured in a 5% CO2, 37°C cell culture incubator for 48 h, the solution in the 96-well plate was discarded, 90 μL of serum-free culture medium and 10 μL of MTT solution (5 mg / mL) were added to each well, after 4 hours of treatment, the solution in the well was aspirated, 100 μL of DMSO was added to each well, the speed was set to 1500 rpm, and the plate was shaken on a 37°C shaker for 10 min. The microplate reader detected the experimental wells at OD The absorbance at 570nm was used to calculate the cell viability. The cell viability was calculated by subtracting the OD of the zero-adjusted well from the OD of the drug-added well and the control well, and then calculating the percentage of the OD value of the drug-added well to the control well.

[0063] exist Figure 1 In the figure, the ribbon-like structure represents the five-membered aggregated Aβ 42 , where A is glutamate-arginine-tryptophan (ERW); B is glutamine-arginine-tryptophan (QRW); C is arginine-arginine-arginine (RRR); D is arginine-arginine-tryptophan (RRW); and E is tryptophan-arginine-arginine (WRR).

[0064] Figure 2 A is Aβ 42 -Aβ 42 Dimer; B is ERW and Aβ 42 Binding; C is QRW and Aβ 42 Binding; D is RRR and Aβ 42 Binding; E is RRW and Aβ 42 Binding; F is WRR and Aβ 42 Combine.

[0065] Figure 4 In the figure, A represents WRR and Aβ 42 B is the binding energy of RRW and Aβ 42 C is the binding energy of ERW and Aβ 42 The binding energy of RRR and Aβ 42 E is the binding energy of QRW and Aβ 42F is the binding energy of the five tripeptides and Aβ 42 A plot of the potential energy of interacting molecules as a function of time.

[0066] Figure 5 **P<0.01, compared with Aβ 42 Compare; $$ P<0.01, compared with Aβ 42 -WRR comparison; ## P<0.01, compared with Aβ 42 -EWR comparison; one-way analysis of variance (ANOVA), using Modified-Tukey test for multiple comparisons between groups, n = 5, and repeated three times.

[0067] Figure 6 A is 10 μM Aβ incubated alone for 48 hours 42 Transmission electron microscopy images; B is 10 μM Aβ 42 Transmission electron microscopy images of cells co-incubated with 40 μM WRR for 48 hours; C is 10 μM Aβ 42 Transmission electron microscopy images of cells incubated with 40 μM ERW for 48 h.

[0068] Figure 7 ELISA assay was used to quantify the effect of WRR or ERW on secreted Aβ 42 The results are shown as mean ± SEM. ns indicates not significant. 42 Group (Aβ) comparison, one-way analysis of variance (ANOVA), Modified-Tukey test for multiple comparisons between groups, n=3.

[0069] Figure 8 In the figure, the protective effects of four oligopeptides on SH-SY5Y cell damage were observed under a microscope (10×). A is blank control; B is transfected with Aβ; C is non-transfected + 50μM WRR; D is transfected + 10μM WRR; E is transfected + 50μM WRR; F is non-transfected + 50μM ERW; G is transfected + 10μM ERW; H is transfected + 50μM ERW.

[0070] Fig. 9 In this study, flow cytometry was used to detect the effects of two tripeptides on secreted Aβ 42Effect of SH-SY5Y cells on the production of reactive oxygen species (ROS) in A and H are blank controls; B is non-transfected + 50μM WRR; C is transfected with Aβ; D is transfected with + 10μM WRR; E is transfected with + 50μM WRR; F is the overlap of AE; I is non-transfected + 50μM ERW; J is transfected with Aβ; K is transfected with + 10μM ERW; L is transfected with + 50μM ERW; M is the overlap of HL; G and N are quantitative analysis of the experimental results of the WRR group and the ERW group. The results are expressed as mean ± SEM. **p < 0.01, one-way analysis of variance (ANOVA), multiple comparisons were performed using Modified-Tukey test, n = 3.

[0071] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Use of a tripeptide compound having an amino acid sequence of WRR in the preparation of a drug for preventing and treating Alzheimer's disease.